share_log

Universe Pharmaceuticals | 6-K: Report of foreign private issuer (related to financial reporting)

Universe Pharmaceuticals | 6-K: Report of foreign private issuer (related to financial reporting)

大自然药业 | 6-K：外国发行人报告（业绩相关）
美股SEC公告 ·  2024/09/21 04:18

Moomoo AI 已提取核心信息

Universe Pharmaceuticals reported financial results for H1 2024 ended March 31. Revenue decreased 30.2% YoY to $12.9M, with TCMD product sales down 26.7% to $6.9M and third-party product sales down 33.9% to $6.0M. Gross margin declined to 26.2% from 33.2% last year.The company reported a net loss of $13.1M, compared to a $0.7M loss in H1 2023. The increased loss was primarily due to a $7.6M change in fair value of short-term investments and $3.1M realized loss on investments. Selling expenses rose 74% to $4.1M on higher advertising costs.As of March 31, Universe had $8.9M in cash, $2.5M in short-term investments, and $14.4M in accounts receivable. The company believes it has sufficient liquidity for the next 12 months. Management is focused on improving sales and managing costs amid challenging market conditions.
Universe Pharmaceuticals reported financial results for H1 2024 ended March 31. Revenue decreased 30.2% YoY to $12.9M, with TCMD product sales down 26.7% to $6.9M and third-party product sales down 33.9% to $6.0M. Gross margin declined to 26.2% from 33.2% last year.The company reported a net loss of $13.1M, compared to a $0.7M loss in H1 2023. The increased loss was primarily due to a $7.6M change in fair value of short-term investments and $3.1M realized loss on investments. Selling expenses rose 74% to $4.1M on higher advertising costs.As of March 31, Universe had $8.9M in cash, $2.5M in short-term investments, and $14.4M in accounts receivable. The company believes it has sufficient liquidity for the next 12 months. Management is focused on improving sales and managing costs amid challenging market conditions.
大自然药业发布了截至2024年3月31日的上半年财务结果。营业收入同比下降30.2%，降至1290万美元，TCMD产品销售下降26.7%，降至690万美元，第三方产品销售下降33.9%，降至600万美元。毛利率从去年的33.2%下降至26.2%。公司报告净亏损为1310万美元，而2023年上半年亏损为70万美元。亏损增加主要是由于短期投资公允价值变动产生的760万美元损失和投资实现的310万美元损失。由于广告成本上升，销售费用上涨74%，达410万美元。截至3月31日，大自然药业现金余额为890万美元，短期投资为250万美元，应收账款为1440万美元。公司相信未来12个月有足够的流动性。管理层专注于在市场环境严峻的情况下改善销售和管理成本。
大自然药业发布了截至2024年3月31日的上半年财务结果。营业收入同比下降30.2%，降至1290万美元，TCMD产品销售下降26.7%，降至690万美元，第三方产品销售下降33.9%，降至600万美元。毛利率从去年的33.2%下降至26.2%。公司报告净亏损为1310万美元，而2023年上半年亏损为70万美元。亏损增加主要是由于短期投资公允价值变动产生的760万美元损失和投资实现的310万美元损失。由于广告成本上升，销售费用上涨74%，达410万美元。截至3月31日，大自然药业现金余额为890万美元，短期投资为250万美元，应收账款为1440万美元。公司相信未来12个月有足够的流动性。管理层专注于在市场环境严峻的情况下改善销售和管理成本。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间